Breast Cancer

ESMO: Immunotherapies Show Promise on Aggressive Breast Cancer

(Brinkwire) - Women with an aggressive type of breast cancer lived longer if they received immunotherapy plus chemotherapy, rather than chemo alone, a major study has found. The results are expected to change the standard of care for women like those in the clinical trial, who had advanced cases of “triple-negative” breast cancer. That form of the disease often resists standard therapies, and survival rates are poor. It is twice

Phosphorylated-p68 Drug With Efficacy in 100 Cancer Cell Lines to Target Triple Negative Breast Cancer

Drugs that target and destroy phosphorylated-p68 (P-p68), an RNA helicase, have the potential to kill cancer, without damaging other tissues as chemotherapy does. P-p68 has recently garnered attention as a molecular target in cancer therapy. It is an ideal target because P-p68 is overexpressed in cancer cells but absent in normal cells. P-p68 has shown to increase the activity of cancer related genes including cyclin D1, c-jun and c-myc. It